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This supplement is based on the proceedings of
the symposium entitled ‘Serious staphylococcal
infections—cyclic lipopeptides: meeting new
challenges’, which was presented at the 17th
European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID) in Munich during
April 2007.
An increasing proportion of serious bacterial
infections are attributable to Gram-positive bac-
teria [1,2]. Of these, Staphylococcus aureus is of
particular clinical signiﬁcance, as both a commu-
nity-acquired and hospital-acquired pathogen
that is associated with high morbidity and mor-
tality rates, and for which the incidence of
antibiotic resistance is increasing [3]. As a conse-
quence, S. aureus represents a signiﬁcant health-
care burden; in the USA, excess costs, length of
hospitalisation and inpatient deaths due to
S. aureus are estimated at $9.5 billion, 2.7 million
days and 12 000 patients per year, respectively
[4]. In a study of 74 patients with methicillin-
resistant S. aureus (MRSA) infections at Vienna
General Hospital in 2002, there were nine deaths,
the median hospital stay was 37 days, and the
median total hospital cost was £6624 [5]. Common
infections related to this species include compli-
cated skin and soft-tissue infections (cSSTIs),
bacteraemia and infective endocarditis. Today’s
challenge for the clinician is how to treat Gram-
positive bacterial infections effectively, given the
increasing diversity of drug-resistant pathogens
and the diminishing treatment options. The cyclic
lipopeptides are the latest new drug class with
activity against resistant staphylococci, and clin-
ical data suggest that daptomycin, the ﬁrst
licensed member, may contribute substantially
to meeting this challenge. Daptomycin is cur-
rently licensed by the European Medicines
Agency for the treatment of cSSTIs, right-sided
endocarditis caused by S. aureus and S. aureus
bacteraemia (SAB) when associated with right-
sided endocarditis or with cSSTIs. It is also
licensed in the USA for the treatment of cSSTIs
and SAB, including SAB associated with right-
sided endocarditis.
The opening article of this supplement focuses
on the growing problem of antibiotic resistance
among Gram-positive bacteria, in particular
MRSA, and the impact on traditional therapeutic
approaches. Hospital-acquired MRSA became
endemic in many hospitals during the 1980s;
however, the problem is no longer conﬁned to the
healthcare setting, with new MRSA strains emerg-
ing in the community (community-acquired
MRSA) in healthy individuals [6]. The glycopep-
tides, in particular vancomycin, are currently the
standard-of-care antibiotics for MRSA infections.
However, their extensive use has led to the
emergence of vancomycin-resistant and -interme-
diate S. aureus (VRSA and VISA, respectively)
strains. The utility of vancomycin therapy in
S. aureus infections is also threatened by vanco-
mycin tolerance and rising MICs associated with
treatment failures.
In the second article, the antimicrobial charac-
teristics of daptomycin are described, and there is
a review of phase III clinical data concerning the
treatment of cSSTIs [7]. In-vitro experiments with
daptomycin, which is bactericidal without being
bacteriolytic, have conﬁrmed a rapid and broad-
spectrum activity against Gram-positive organ-
isms. Daptomycin was shown not to be inferior to
the comparator regimens (vancomycin and pen-
icillinase-resistant penicillins) for the treatment of
both methicillin-sensitive S. aureus (MSSA) and
MRSA cSSTIs [7]. Compared with comparator
therapies, a signiﬁcant difference in favour of
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daptomycin was observed in the time to clinical
resolution [7]. The safety proﬁle of this drug was
similar to that of the comparators [7]. This article
also considers the potential of daptomycin in the
treatment of bacteraemia and infective endocar-
ditis. In an open-label trial to investigate the
treatment of bacteraemia caused by S. aureus with
or without endocarditis, daptomycin was found
to be non-inferior to standard therapy in terms of
clinical success [8]. It was equally effective in the
treatment of right-sided endocarditis caused by
MSSA, and potentially superior to vancomycin in
the treatment of right-sided endocarditis caused
by MRSA [8].
Two case studies highlighting the potential
complications in the treatment and diagnosis of
cSSTIs are discussed in the third article. A case of
an S. aureus-infected leg ulcer highlights the
importance of individualising treatment accord-
ing to a combination of drug toxicity proﬁles and
sensitivity testing of bacterial isolates. The second
case, of a diabetic foot ulcer, underlines current
concerns regarding the clinical signiﬁcance of
vancomycin MIC ‘creep’ and the importance of
appropriate empirical therapy.
Future strategies for treating S. aureus blood-
stream infections are discussed in the ﬁnal article
of the supplement. New management strategies
are required to improve early diagnosis of SAB,
rapid identiﬁcation of infecting pathogens, and
the development of new antibiotics that are
effective against both MSSA and MRSA. Early
identiﬁcation of bloodstream infections, com-
bined with appropriate antibiotic therapy, will
reduce the risk of complications such as endo-
carditis. A scoring system based on the presence
of clinical risk-factors has been developed to
predict complicated SAB, and could have a role
in the early identiﬁcation of SAB [9]. New
methods of pathogen identiﬁcation using the
PCR technique are also being developed, and
facilitate the detection and identiﬁcation of the
most important bacterial and fungal species
causing bloodstream infections within hours
rather than days. Finally, the introduction of
new, broad-spectrum antibiotics that are effective
against both MSSA and MRSA is essential, given
the increasing prevalence of MRSA in both
hospital and community settings. The advan-
tages of recently introduced antibiotics, such as
daptomycin, and others currently under devel-
opment are discussed.
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